Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Europe
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 17-(cyclobutylmethyl)morphinan-3,14-diol
2. Apo-butorphanol
3. Bc 2627
4. Bc-2627
5. Bc2627
6. Beforal
7. Butorphanol
8. Butorphanol Tartrate
9. Dolorex
10. Moradol
11. Stadol
12. Stadol Ns
13. Torbugesic
1. Butorphanol Tartrate
2. 58786-99-5
3. Butorphanol (+)-tartrate Salt
4. Stadol (tn)
5. Butorphanol Tartrate Salt
6. Butorphanol Tartrate (jan/usp)
7. Akos015994595
8. Hs-0001
9. Butorphanol (+)-tartrate Salt, >=99%
10. D00837
11. 786b995
12. Butorphanol Tartrate, United States Pharmacopeia (usp) Reference Standard
1. Butorfanol
2. Torate
3. Torbutrol
| Molecular Weight | 477.5 g/mol |
|---|---|
| Molecular Formula | C25H35NO8 |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 5 |
| Exact Mass | 477.23626707 g/mol |
| Monoisotopic Mass | 477.23626707 g/mol |
| Topological Polar Surface Area | 159 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 626 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Butorphanol tartrate |
| Drug Label | Butorphanol tartrate is a synthetically derived opioid agonist-antagonist analgesic of the phenanthrene series. The chemical name is (-)-17-(cyclobutylmethyl) morphinan-3, 14-diol [S-(R*,R*)] 2,3 dihydroxybutanedioate (1:1) (salt). The molecul... |
| Active Ingredient | Butorphanol tartrate |
| Dosage Form | Injectable; Spray, metered |
| Route | Nasal; Injection |
| Strength | 2mg/ml; 1mg/ml; 1mg/spray |
| Market Status | Prescription |
| Company | Bedford; Hikma Farmaceutica; Novex; Mylan; Roxane |
| 2 of 2 | |
|---|---|
| Drug Name | Butorphanol tartrate |
| Drug Label | Butorphanol tartrate is a synthetically derived opioid agonist-antagonist analgesic of the phenanthrene series. The chemical name is (-)-17-(cyclobutylmethyl) morphinan-3, 14-diol [S-(R*,R*)] 2,3 dihydroxybutanedioate (1:1) (salt). The molecul... |
| Active Ingredient | Butorphanol tartrate |
| Dosage Form | Injectable; Spray, metered |
| Route | Nasal; Injection |
| Strength | 2mg/ml; 1mg/ml; 1mg/spray |
| Market Status | Prescription |
| Company | Bedford; Hikma Farmaceutica; Novex; Mylan; Roxane |
Antitussive Agents
Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally. (See all compounds classified as Antitussive Agents.)
Narcotics
Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)
Analgesics, Opioid
Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)
Narcotic Antagonists
Agents inhibiting the effect of narcotics on the central nervous system. (See all compounds classified as Narcotic Antagonists.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Parenteral
Controlled & Modified Release
Solubilizers
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Butorphanol Tartrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Butorphanol Tartrate, including repackagers and relabelers. The FDA regulates Butorphanol Tartrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Butorphanol Tartrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Butorphanol Tartrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Butorphanol Tartrate supplier is an individual or a company that provides Butorphanol Tartrate active pharmaceutical ingredient (API) or Butorphanol Tartrate finished formulations upon request. The Butorphanol Tartrate suppliers may include Butorphanol Tartrate API manufacturers, exporters, distributors and traders.
click here to find a list of Butorphanol Tartrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Butorphanol Tartrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Butorphanol Tartrate active pharmaceutical ingredient (API) in detail. Different forms of Butorphanol Tartrate DMFs exist exist since differing nations have different regulations, such as Butorphanol Tartrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Butorphanol Tartrate DMF submitted to regulatory agencies in the US is known as a USDMF. Butorphanol Tartrate USDMF includes data on Butorphanol Tartrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Butorphanol Tartrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Butorphanol Tartrate suppliers with USDMF on PharmaCompass.
A Butorphanol Tartrate written confirmation (Butorphanol Tartrate WC) is an official document issued by a regulatory agency to a Butorphanol Tartrate manufacturer, verifying that the manufacturing facility of a Butorphanol Tartrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Butorphanol Tartrate APIs or Butorphanol Tartrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Butorphanol Tartrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Butorphanol Tartrate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Butorphanol Tartrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Butorphanol Tartrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Butorphanol Tartrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Butorphanol Tartrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Butorphanol Tartrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Butorphanol Tartrate suppliers with NDC on PharmaCompass.
Butorphanol Tartrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Butorphanol Tartrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Butorphanol Tartrate GMP manufacturer or Butorphanol Tartrate GMP API supplier for your needs.
A Butorphanol Tartrate CoA (Certificate of Analysis) is a formal document that attests to Butorphanol Tartrate's compliance with Butorphanol Tartrate specifications and serves as a tool for batch-level quality control.
Butorphanol Tartrate CoA mostly includes findings from lab analyses of a specific batch. For each Butorphanol Tartrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Butorphanol Tartrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Butorphanol Tartrate EP), Butorphanol Tartrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Butorphanol Tartrate USP).
LOOKING FOR A SUPPLIER?
